Abstract Number: 109 • 2018 ACR/ARHP Annual Meeting
Unique miRNA Signatures Detected in Extracellular Vesicles from Patients with Systemic Lupus Erythematous
Background/Purpose: Recent studies have identified distinct changes in cellular miRNA (miR) expression associated with systemic lupus erythematous (SLE). We have previously shown that toll-like receptor…Abstract Number: 110 • 2018 ACR/ARHP Annual Meeting
Single-Cell RNA-Seq Analysis of ANA+ Healthy and SLE Patients Show Variations in Activated Stress Response and Regulatory Pathways
Background/Purpose: One hallmark of the autoimmune disease Systemic lupus erythematosus (SLE) is the presence of antinuclear antibodies (ANAs). While the specificities and levels can indicate…Abstract Number: 111 • 2018 ACR/ARHP Annual Meeting
BAFF Inhibition Attenuates Fibrosis in Bleomycin-Induced Scleroderma Model Via Modulating the Regulatory and Effector B-Cell Balance
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and lung fibrosis. Over 90% of patients with SSc are positive for autoantibodies. In…Abstract Number: 112 • 2018 ACR/ARHP Annual Meeting
Evidence for Altered Peroxisome Proliferator Activated Receptor (PPAR) Pathway Activity in a Transgenic Mouse Model of Scleroderma (TβRIIΔk-fib): Analysis of Mouse Skin, Lung and Explanted Cells
Background/Purpose: The TβRIIΔk-fib transgenic (TG) mouse model of scleroderma carries a fibroblast-specific TGFβ receptor II mutation resulting in balanced up-regulation of TGFβ signalling and replicates…Abstract Number: 113 • 2018 ACR/ARHP Annual Meeting
Epigenetic Changes in Dermal Fibroblasts By Inhibition of DOT1L Affect Cell Proliferation and Cell Cycle, but Have No Direct Effects on Collagen Deposition in in Vitro and In Vivo models of Fibrosis
Background/Purpose: Fibrosis is a key feature of systemic sclerosis, a devastating disease that is not well understood. The role of epigenetic factors in the pathophysiology…Abstract Number: 114 • 2018 ACR/ARHP Annual Meeting
Antifibrotic Regulation By Response Gene to Complement 32 Protein
Background/Purpose: Pulmonary fibrosis is a serious problem in patients with scleroderma lung disease (SLD). Better therapies for pulmonary fibrosis are urgently needed. Identification of new…Abstract Number: 115 • 2018 ACR/ARHP Annual Meeting
CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients
Background/Purpose: CTLA4-Ig interacts with the cell surface costimulatory molecule CD86 and can downregulate the target cell activation [1]. Circulating fibrocytes (CFs) express markers of both…Abstract Number: 116 • 2018 ACR/ARHP Annual Meeting
Identifying Matricellular Protein CYR61 As a Potential Anti-Fibrotic and Pro-Angiogenic Mediator in Scleroderma
Background/Purpose: Vascular abnormalities represent a fundamental event in the pathogenesis of scleroderma (SSc) in that endothelial cell (EC) damage triggers a self-fueling process ending in…Abstract Number: 117 • 2018 ACR/ARHP Annual Meeting
Hypomorphic A20 Expression Modulates Fibrosis Susceptibility: Implications for Systemic Sclerosis?
Background/Purpose: Mutiple organ fibrosis, a hallmark of systemic sclerosis (SSc), remains poorly understood. Recent GWAS have uncovered consistent genetic linkage between TNFAIP3, encoding the ubiquitin-editing…Abstract Number: 118 • 2018 ACR/ARHP Annual Meeting
Pharmacological Inhibition of JAK/STAT Signaling By Tofacitinib Prevents Experimental Organ Fibrosis: Novel Therapy for Systemic Sclerosis
Background/Purpose: Synchronous fibrosis in systemic sclerosis (SSc) leads to failure of the skin, lungs and other organs, and has no effective treatments. Myofibroblast activation underlies…Abstract Number: 119 • 2018 ACR/ARHP Annual Meeting
Targeting Dysregulated CD38/NAD+ Homeostasis Mitigates Multiple Organ Fibrosis
Background/Purpose: Persistent myofibroblast activation underlies unresolving multi-organ fibrosis in systemic sclerosis (SSc). We had shown that fibrosis is associated with reduced expression of NAD-dependent sirtuins…Abstract Number: 120 • 2018 ACR/ARHP Annual Meeting
An Orally Available Highly Selective 5-Hydroxytryptamine 2B Receptor Antagonist Ameliorating Pulmonary and Dermal Fibrosis in Preclinical Models of Systemic Sclerosis
Background/Purpose: Serotonin or 5-hydroxytryptamine (5-HT) is well known as a stimulator of tissue fibrosis and a significant role of peripheral 5-HT2B receptors in fibrosis has…Abstract Number: 121 • 2018 ACR/ARHP Annual Meeting
Inhibition of Nuclear Receptor Coactivator 3 Attenuates Fibrosis in Murine Models of Systemic Sclerosis
Background/Purpose: Uncontrolled activation of fibroblasts releasing large amounts of extracellular matrix proteins is a key feature of systemic sclerosis (SSc). The nuclear receptor coactivators (NCOA)…Abstract Number: 122 • 2018 ACR/ARHP Annual Meeting
Metformin Inhibited the Development of Bleomycin-Induced Murine Scleroderma Via Restoring the Balance between Regulatory and Effector T Cells and Suppressing Spleen Germinal Center Formation
Background/Purpose: Scleroderma is a multisystem connective tissue disease characterized by extensive tissue fibrosis and its three prominent cardinal features are vasculopathy, excessive collagen deposition and immunological abnormalities. Metformin (MET)…Abstract Number: 123 • 2018 ACR/ARHP Annual Meeting
Non-Hematopoietic Derived TNF Drives Pulmonary Vasculopathy: A New Model of CTD-Associated Pulmonary Hypertension
Background/Purpose: Cardiopulmonary disease is a severe comorbidity in many connective tissue diseases (CTD). Rheumatoid arthritis, systemic sclerosis, and systemic lupus patients are all at increased…
ACR Meeting Abstracts